Despite Landfar Bio-medicine's falling price and revenues, i...
Despite Landfar Bio-medicine's falling price and revenues, its high P/S ratio suggests investor optimism. However, inconsistent revenue growth and expected industry growth of 825% may make these prices unsustainable. Without significant medium-term performance improvement, the P/S ratio may decline to a more reasonable level.
Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment